<DOC>
	<DOCNO>NCT00278590</DOCNO>
	<brief_summary>This trial design evaluate safety treat systemic lupus erythematosus participant cyclophosphamide CAMPATH-1H follow allogeneic stem cell transplant . There randomization study . All subject determine eligible study treatment receive cyclophosphamide CAMPATH-1H follow allogeneic stem cell transplant . The purpose intense chemotherapy destroy cell immune system may cause disease . The purpose stem cell infusion produce normal immune system longer attack body . The study purpose examine whether treatment result improvement lupus disease .</brief_summary>
	<brief_title>Allogeneic Stem Cell Transplantation Systemic Lupus Erythematosus</brief_title>
	<detailed_description>This phase I study design select patient refractory intractable disease . SLE patient impaired visceral organ function chronic exposure glucocorticoid therapy complicate significant morbidity , frequent hospitalization high-risk mortality . For participant indication nephritis , active disease must present despite least 6 cycle monthly pulse cyclophosphamide . Participants extra-renal lupus need fail 3 month monthly cyclophosphamide . Patients HLA match sibling , offer allogeneic HSCT . Because high transplant relate toxicity mortality conventional myeloablative regimen , utilize mini-conditioning regimen . To minimize GvHD , candidate must 50 year old young vivo CAMPATH use condition regimen deplete infuse donor lymphocyte . Peripheral Blood Stem Cell ( PBSC ) Harvest Donor PBSC mobilize G-CSF 10 mcg/kg/day ( dose may adjust 5-16 mcg/kg/day PI toxicity , e.g . flu-like symptom ) stem cell collection begin day 4 . Leukapheresis may repeat three consecutive day . 1 ) If criteria meet patient ( recipient ) may treat . 1 . CD34+ cell count &gt; 2.0 x106 CD34+ cells/kg recipient weight 2 . Gram stein negative 3 . Culture negative ( 14 day ) 4 . Cell viability time final formulation cyroprotectant mediaâ‰¥ 70 % Conditioning Regimen Cyclophosphamide 50mg/kg/day x 4 day give IV 1 hour 500 cc normal saline . If actual weight &lt; ideal weight , cyclophosphamide give base actual weight . If actual weight &gt; ideal weight , cyclophosphamide give adjusted weight . Adjusted weight = ideal weight + 25 % ( actual weight minus ideal weight ) . Mesna 50mg/kg/day give IV 24 hour 250 cc normal saline D5W start 2 hour first cyclophosphamide dose . Weight base calculate cyclophosphamide . Hydration approximately 50-200cc/hour adult begin 6 hour cyclophosphamide continue 24 hour last cyclophosphamide dose . Hydration rate need individually adjust daily weight maintain dry weight count . BID weight obtain . Warning : Participants renal insufficiency prone volume overload . Early institution ultra filtration dialysis recommend . Three-way bladder irrigation may need participant tolerate fluid hydration cyclophosphamide administration 24 hour last dose cyclophosphamide . In patient hemodialysis , cyclophosphamide give even hemodialysis perform morning daily last dose cyclophosphamide administer . Close coordination nephrology service require . CAMPATH-1H 30mg/day x 2 day ( dose adjustment ) give IV 2 hour 100 cc normal saline . Premedication acetaminophen 650mg benadryl 50mg PO/IV give 30-60min infusion . These medication repeat need . Solumedrol 1 gram give IV 30 min prior CAMPATH-1H . G-CSF 5 mcg/kg/day start day 6 engraftment occur . It continue absolute neutrophil count reach least 500/ul . The dose may round order waste medication vial . NOTE : GCSF may start earlier , e.g . day 0 , per investigator 's discretion . Cyclosporine* start day -3 200 mg po BID adjust HPLC level 150 - 250 toxicity ( e.g. , tremor , renal insufficiency , TTP , etc. ) . CSA continue 2 month unless stop toxicity . If patient tolerate oral cycloporine , intravenous cyclosporine continuous infusion ( 3mg/kg/24hours ) adjust level use . Mycophenolate mofetil ( MMF ) * 1g PO/IV q 12 hr start day -3 continue 6 month . The dosage adjust tapered stopping , unless toxicity mandate abrupt cessation . MMF adjust PI accord toxicity , GVHD , donor engraftment donor chimerism . *Cyclosporine MMF guideline dosage duration modify accord investigator discretion base side effect , renal function , CBC GVHD status .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Recipient Ages 18 50 year old . Meet least 4 11 American College Rheumatology ( ACR ) Classification criterion SLE ( see Appendix 1 ) . Able give inform consent . HLA match sibling donor available . Meet one follow three : 1 . For lupus nephritis , participant must fail pulse cyclophosphamide ( 500 1000 mg/m2 monthly minimum 6 month ) . Failure define meeting criterion consider BILAG ( Appendix 4 ) renal category A . If indication HSCT nephritis , renal biopsy must obtain document either class III IV glomerulonephritis . 2 . For visceral organ involvement nephritis , participant must BILAG cardiovascular/respiratory category A , vasculitis category A , neurologic category A must fail least 3 month oral IV cyclophosphamide corticosteroid dependent . Steroid dependence define least 3 month steroid therapy inability wean corticosteroid le 20 mg/day prednisone equivalent . 3 . For cytopenias immune mediate , participant must BILAG hematologic category A . Participants must inability maintain platelet &gt; 15,000 , inability prevent active bleeding without transfusion , inability maintain hemoglobin &gt; 7.0 , inability prevent cardiovascular disease without transfusion . In addition , participant must fail corticosteroid ( either oral prednisone &gt; 0.5 mg/kg/day 6 month pulse methylprednisolone least one cycle three day ) , refractory IVIG , least one following : azathioprine 2 mg/kg/day least 3 month , mycophenolate mofetil 2 gram daily 3 month , cyclophosphamide intravenously orally least 3 month , cyclosporine least 3 mg/kg/day least 3 month , danazol least 3 month , splenectomy . Recipient HIV positive . Ongoing malignancy except localize basal cell squamous skin cancer . Other malignancy participant judge cured local surgical therapy , head neck cancer , stage I II breast cancer consider individual basis investigator final screening participant qualification . Positive pregnancy test , inability unwillingness pursue effective mean birth control , failure willingly accept comprehend irreversible sterility side effect therapy . Psychiatric illness mental deficiency make compliance treatment inform consent impossible . DLCO &lt; 45 % predict unless attribute solely active lupus . Resting LVEF &lt; 40 % unless due active lupus . Known hypersensitivity E. Coli derive protein . Transaminases great 2 time normal unless due active lupus . Any illness opinion investigator would jeopardize ability patient tolerate treatment . Donor Inclusion Criteria Donor must HLA identical sibling HLA match cord blood donor . If donor HLA match sibling , donor must &gt; 18 year age less 50years old . If multiple HLA match donor available , preference give samesex , CMV status , nulliparous donor , case cord blood higher nucleated cell count . If donor HLA match cord blood , cord blood stem cell obtain New York Blood Center Cord Blood Registry ( Tel 2125703230 ) internationally recognize registry , match available , Stemcyte ( 6268219860 ) commercial registry specialize minority donor National Marrow Donor Program ( NMDP ) . One unit HLA match cord blood unit infuse day zero . Donor Exclusion Criteria Physiologic age &gt; 50 year old &lt; 18 year old . HIV positive . Active ischemic heart disease heart failure . Acute chronic active hepatitis . Uncontrolled diabetes mellitus illness opinion investigator would jeopardize ability donor tolerate stem cell collection . Prior history malignancy except localize basal cell squamous skin cancer . Other malignancy patient judge cured local surgical therapy , ( limit ) head neck cancer , stage I II breast cancer consider individual basis . Positive pregnancy test . Positive ANA antids DNA . Psychiatric illness mental deficiency make compliance treatment inform consent impossible . Major hematological abnormality platelet count less 150,000/ul , ANC le 1000/ul . If donor sibling must collect minimum 2 . 106CD34+ cells/kg proceed Transplant . If donor cord blood unit ( ) minimum number nucleated cell available must 2 x 107 /kg . To achieve number nucleated cell , two unit HLA match cord blood may utilize . ( Wagner JE Blood . 2005 Feb 1 ; 105 ( 3 ) :13437 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>